Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

TJ0113

Source date not recordedAnalyse record ↗

Mitophagy-activating small molecule in a recruiting Phase 2 sarcopenia study after completed Phase 2 Parkinson's-disease testing.

Modality
oral small-molecule selective mitophagy activator
Availability (US)
Phase 2 sarcopenia study Recruiting; Phase 2 Parkinson's-disease study Completed
Biomarkers
400-meter walk gait speed; appendicular skeletal-muscle mass; grip strength; adverse events
Hallmark targeted
mitochondrial dysfunction, mitophagy, skeletal-muscle aging
Kind
investigational drug
Clinical trials
NCT07620938 — Phase 2, Recruiting on August 5, 2026 update; NCT06596005 — Phase 2, Completed on January 16, 2026 update